Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KQB198 as Monotherapy and in Combination With Anticancer Agents in Advanced Hematologic Malignancies
NCT06645886Phase 1Active, not recruiting
- Sponsor
- Kumquat Biosciences
- Start
- Dec 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of KQB198 in chronic myeloid leukemia (CML) (6 arms), sponsored by Kumquat Biosciences. Primary endpoints: Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities at 28 Days, Recommended Phase 2 Dose up to 30 months and 1 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
KQB198
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06645886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06645886.